Literature DB >> 5067997

Endocrine exophthalmos.

.   

Abstract

Mesh:

Substances:

Year:  1972        PMID: 5067997      PMCID: PMC1785587     

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


× No keyword cloud information.
  10 in total

1.  Euthyroid patients with early eye signs of Graves' disease; their responses to L-triiodothyronine and thyrotropin.

Authors:  S C WERNER
Journal:  Am J Med       Date:  1955-04       Impact factor: 4.965

2.  Water and mucopolysaccharide as structural components of connective tissue.

Authors:  J H FESSLER
Journal:  Nature       Date:  1957-02-23       Impact factor: 49.962

3.  Transantral orbital decompression for malignant exophthalmos.

Authors:  T E WALSH; J H OGURA
Journal:  Laryngoscope       Date:  1957-06       Impact factor: 3.325

4.  The thyroid-stimulating hormone of the anterior pituitary as distinct from the exophthalmos-producing substance.

Authors:  B M DOBYNS; S L STEELMAN
Journal:  Endocrinology       Date:  1953-06       Impact factor: 4.736

5.  Observations on the course of exophthalmos after 131-I therapy.

Authors:  D I Jones; D S Munro; G M Wilson
Journal:  Proc R Soc Med       Date:  1969-01

6.  Transmaxillary orbital decompression for malignant exophthalmos.

Authors:  P M Stell
Journal:  Proc R Soc Med       Date:  1969-01

7.  Effect of thyroid ablation on dysthyroid exophthalmos.

Authors:  I T Boyle; W R Greig; J A Thomson; J Winning; E M McGirr
Journal:  Proc R Soc Med       Date:  1969-01

8.  Investigation of endocrine exophthalmos.

Authors:  A N Bowden; F C Ross
Journal:  Proc R Soc Med       Date:  1969-01

9.  Endocrine exophthalmos. Concepts and surgical management.

Authors:  R B Sessions; R B Wilkins; J S Weycer
Journal:  Arch Otolaryngol       Date:  1972-01

10.  Graves's disease and total thyroidectomy. Progression of severe eye changes and decrease in serum long acting thyroid stimulator after operation.

Authors:  S C Werner; C R Feind; M Aida
Journal:  N Engl J Med       Date:  1967-01-19       Impact factor: 91.245

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.